Orlistat 1 A Pharma (Orlistat)

Orlistat is indicated for the management of obesity and related metabolic conditions.

• Obesity: helps achieve weight loss when combined with a reduced‑calorie, low‑fat diet.
• Overweight with comorbidities: supports weight reduction in patients with a BMI ≥ 27 kg/m² who have hypertension, dyslipidaemia, or type 2 diabetes.
• Weight‑maintenance after loss: aids in maintaining weight loss achieved through diet and lifestyle changes.
• Prevention of weight‑gain associated with antipsychotic therapy: may limit weight increase in patients receiving certain psychiatric medications.
• Adjunct to lifestyle therapy in metabolic syndrome: contributes to overall risk‑factor improvement when used with diet and exercise.

• Orlistat acts locally in the gastrointestinal tract by covalently binding to the active site of gastric and pancreatic lipases. This inhibition prevents the enzymatic breakdown of dietary triglycerides into absorbable free fatty acids and monoglycerides, thereby reducing the amount of fat absorbed from the intestine and promoting its excretion in the feces.

Orlistat may cause a range of gastrointestinal and systemic reactions.

Common Side Effects

• Oily spotting: oily droplets on under‑clothing or skin.
• Fecal urgency: sudden need to defecate.
• Fatty/oily stool: pale, greasy, foul‑smelling stools.
• Flatulence with discharge: increased gas and possible oily discharge.
• Abdominal cramping: intermittent stomach pain.
• Reduced absorption of fat‑soluble vitamins: lower levels of vitamins A, D, E, K.

Serious or Rare Side Effects

• Acute liver injury: sudden onset of jaundice or elevated liver enzymes.
• Severe allergic reaction: rash, itching, swelling, dizziness, or trouble breathing.
• Pancreatitis: intense abdominal pain radiating to the back.
• Kidney stones: flank pain, blood in urine, or urinary obstruction.
• Persistent diarrhea: watery stools lasting more than two weeks.
• Unexplained weight loss: rapid loss not related to diet changes.

Orlistat should be used with caution and under medical supervision.

• Assess BMI: confirm patient meets BMI criteria before initiating therapy.
• Monitor vitamin levels: supplement fat‑soluble vitamins (A, D, E, K) regularly.
• Review concomitant medications: evaluate for drugs that require fat‑based absorption.
• Counsel on low‑fat diet: advise patients to limit dietary fat to ≤30 g per day.
• Observe for liver function changes: periodic liver enzyme testing is advisable.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Orlistat can interact with several medicines, affecting their absorption or efficacy.

Major Interactions (Avoid)

• Cytochrome P450 inhibitors: may increase systemic exposure of co‑administered drugs.
• Warfarin: reduced vitamin K absorption can alter anticoagulant effect.
• Levothyroxine: decreased absorption may require dose adjustment.

Moderate Interactions (Monitor Closely):

• Fat‑soluble vitamin supplements: timing must be separated by at least 2 hours.
• Orph or  ");